EdgeMarket › What Nea Management Company, Llc reported owning
What Nea Management Company, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.8BPositions
26Quarter
2026-03-31Shown below
26largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| unmapped CUSIP 03940C100 | 349.7M | 19.9% | 3.0M | — | — |
| CELC Celcuity Inc. | 260.9M | 14.8% | 2.3M | 93.53 | +91.8% |
| SGP SpyGlass Pharma, Inc. | 191.5M | 10.9% | 7.4M | 26.51 | — |
| TRVI Trevi Therapeutics, Inc. | 157.7M | 9.0% | 13.2M | 17.96 | +142.0% |
| SVRA Savara Inc | 133.6M | 7.6% | 24.5M | 5.59 | +80.9% |
| GLUE Monte Rosa Therapeutics, Inc. | 126.5M | 7.2% | 7.7M | 14.30 | +222.8% |
| MBX MBX Biosciences, Inc. | 107.9M | 6.1% | 3.6M | 66.33 | +386.6% |
| ZBIO Zenas BioPharma, Inc. | 78.7M | 4.5% | 4.0M | 32.29 | +97.9% |
| COUR Coursera, Inc. | 74.9M | 4.3% | 12.9M | 6.00 | -47.2% |
| AUPH Aurinia Pharmaceuticals Inc. | 58.8M | 3.3% | 4.0M | 16.65 | +38.6% |
| ORIC Oric Pharmaceuticals, Inc. | 52.2M | 3.0% | 4.1M | 14.20 | +49.3% |
| CRSP CRISPR Therapeutics AG | 50.4M | 2.9% | 1.1M | 59.50 | +12.1% |
| PHAT Phathom Pharmaceuticals, Inc. | 21.8M | 1.2% | 2.0M | 8.87 | -16.6% |
| CVRX CVRx, Inc. | 19.2M | 1.1% | 2.0M | 2.84 | -60.6% |
| KRRO Korro Bio, Inc. | 14.7M | 0.8% | 1.3M | 13.18 | -31.6% |
| unmapped CUSIP 98420X103 | 13.4M | 0.8% | 3.2M | — | — |
| CSBR CHAMPIONS ONCOLOGY, INC. | 9.9M | 0.6% | 1.7M | 4.96 | -32.2% |
| BDTX Black Diamond Therapeutics, Inc. | 9.5M | 0.5% | 4.4M | 2.21 | -15.0% |
| IVA Inventiva S.A. | 8.0M | 0.5% | 1.5M | 4.68 | +2.2% |
| NKTX Nkarta, Inc. | 7.5M | 0.4% | 3.6M | 2.66 | +17.7% |
| LONA LeonaBio, Inc. | 4.8M | 0.3% | 464.4K | 7.68 | +92.8% |
| SNTI Senti Biosciences Holdings, Inc. | 3.1M | 0.2% | 3.8M | 0.39 | -75.4% |
| MRKR Marker Therapeutics, Inc. | 2.1M | 0.1% | 1.6M | 1.39 | +19.8% |
| OKUR OnKure Therapeutics, Inc. | 2.0M | 0.1% | 478.5K | 3.94 | +44.3% |
| GOSS Gossamer Bio, Inc. | 328.5K | 0.0% | 1.0M | 0.15 | -92.1% |
| IMA ImageneBio, Inc. | 250.0K | 0.0% | 50.0K | 5.51 | -60.8% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →